Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;16(1):62-5.
doi: 10.7861/clinmedicine.16-1-62.

Non-melanoma skin cancer

Liezel L Griffin  1 , Faisal Rehman Ali  2 , John T Lear  3
Affiliations

Non-melanoma skin cancer

Liezel L Griffin et al. Clin Med (Lond). 2016 Feb.

Abstract

Non-melanoma skin cancer (NMSC) comprises basal cell carcinoma (BCC) and squamous cell carcinoma, together with a host of rare tumours. NMSC is the commonest malignancy among Caucasians and its incidence continues to rise annually. Exposure to UV radiation initiates approximately 90% of NMSC, causing malignant transformation of keratinocytes and suppression of the inflammatory response. Risk factors include sun exposure and immunosuppression. There are several subtypes of BCC, although histological overlap is common. Surgery has traditionally been regarded as the 'gold-standard' treatment, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (radiotherapy, curettage and cautery, and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). The recent development of novel hedgehog pathway inhibitors for high-risk BCC (including oral vismodegib and sonidegib) may represent a paradigm shift towards medical management of NMSC.

Keywords: Non-melanoma skin cancer; basal cell carcinoma; dermatology; squamous cell carcinoma; surgery.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Basal cell carcinoma. Reproduced with permission of Salford Royal NHS Foundation Trust.
Fig 2.
Fig 2.
Squamous cell carcinoma. Reproduced with permission of Salford Royal NHS Foundation Trust.
Fig 3.
Fig 3.
Superficial BCC (a) before and (b) after treatment with photodynamic therapy. Reproduced with permission of Salford Royal NHS Foundation Trust.
See this image and copyright information in PMC

References

    1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol 2012;166:1069–80. - PubMed
    1. Leigh IM. Progress in skin cancer: the U.K. experience. Br J Dermatol 2014;171:443–5. - PubMed
    1. Ali FR, Lear JT. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC. Br J Dermatol 2013;169:53–7. - PubMed
    1. Cancer Research UK. Skin cancer statistics. London: CRUK, 2015. Available online at www.cancerresearchuk.org/health-professional/cancer-statistics/statistic... [Accessed 26 November 2015]
    1. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191–6. - PMC - PubMed